109.35
price up icon1.90%   2.04
after-market Handel nachbörslich: 109.35
loading

Novartis Ag Adr Aktie (NVS) Neueste Nachrichten

pulisher
Feb 21, 2025

NVS: 3 Gene Therapy Stocks With Game-Changing Potential - StockNews.com

Feb 21, 2025
pulisher
Feb 21, 2025

Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight - GlobeNewswire Inc.

Feb 21, 2025
pulisher
Feb 18, 2025

NVS Quantitative Stock Analysis - Nasdaq

Feb 18, 2025
pulisher
Feb 13, 2025

Company’s Banking Stock: Dissecting a 2.21% Quarterly Revenue Decline Amid Growth - The InvestChronicle

Feb 13, 2025
pulisher
Feb 11, 2025

Novartis to buy Anthos Therapeutics in $3.1bn deal - Proactive Investors USA

Feb 11, 2025
pulisher
Feb 09, 2025

Novartis 2017 Financial Results - Novartis

Feb 09, 2025
pulisher
Feb 07, 2025

ATI Inc [ATI] Records 200-Day SMA of $59.51 - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

Taking a look at what insiders are doing to gauge the America Movil S.A.B.DE C.V. ADR (AMX)’s direction - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

Novartis AG ADR [NVS] Officer makes an insider purchase of 6,566 shares worth 0.73 million. - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

NVS’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Feb 07, 2025
pulisher
Feb 07, 2025

Novartis AG ADR (NVS) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News

Feb 07, 2025
pulisher
Feb 06, 2025

Novartis AG ADR [NVS] is 12.85% higher this YTD. Is it still time to buy? - The DBT News

Feb 06, 2025
pulisher
Feb 06, 2025

Delhi High Court grants ad interim injunction to leading pharmaceutical company NOVARTIS; restrains use of NOVITAS mark - SCC Online

Feb 06, 2025
pulisher
Feb 03, 2025

HSBC Securities downgrades Novartis AG ADR (NVS) rating to a Reduce - Knox Daily

Feb 03, 2025
pulisher
Feb 03, 2025

2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond - sharewise

Feb 03, 2025
pulisher
Feb 03, 2025

Novartis's SWOT analysis: pharma giant's stock navigates generic headwinds - Investing.com

Feb 03, 2025
pulisher
Feb 01, 2025

Novartis Earnings: Results In-Line; Growth Brands to Offset Entresto Loss of Exclusivity in 2025 - Morningstar

Feb 01, 2025
pulisher
Jan 31, 2025

Novartis Financial Results – Q2 2023 - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

World Economic Forum Annual Meeting 2025 - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis Posts Q4 Earnings And Sales Beat, Shares Gain - Barchart

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis 2022 Financial Results - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis at ASH - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis 2021 Financial Results - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis Financial Results – Q1 2023 - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis ADR earnings beat by $0.16, revenue topped estimates - Investing.com South Africa

Jan 31, 2025
pulisher
Jan 31, 2025

J.P. Morgan Healthcare Conference 2024 - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis Posts Q4 Earnings and Sales Beat, Shares Gain - Nasdaq

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis 2023 Financial Results - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis Financial Results – Q2 2024 - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Building belonging - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis in Society Integrated Report 2024 - Novartis

Jan 31, 2025
pulisher
Jan 28, 2025

Novartis to Report Q4 Earnings: What's in the Offing? - Yahoo Finance

Jan 28, 2025
pulisher
Jan 28, 2025

AI Pharma: 2 Paths to AI-Powered Drug Investment - sharewise

Jan 28, 2025
pulisher
Jan 24, 2025

Inari Medical Inc (NASDAQ: NARI): Getting A Free Pass? - Stocks Register

Jan 24, 2025
pulisher
Jan 24, 2025

Metrics That Matter About Deutsche Bank AG (NYSE: DB) - Stocks Register

Jan 24, 2025
pulisher
Jan 17, 2025

7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.

Jan 17, 2025
pulisher
Jan 10, 2025

Saudi Arabia Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 10, 2025
pulisher
Jan 09, 2025

South Korea Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025
pulisher
Jan 09, 2025

Thailand Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025
pulisher
Jan 09, 2025

Japan Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025
pulisher
Jan 09, 2025

The United States Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025
pulisher
Jan 09, 2025

The UAE Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025
pulisher
Jan 09, 2025

Canada Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025
pulisher
Jan 06, 2025

Weekly Upgrades and Downgrades - InvestorPlace

Jan 06, 2025
drug_manufacturers_general MRK
$89.50
price up icon 2.08%
$303.01
price up icon 1.71%
drug_manufacturers_general PFE
$26.30
price up icon 1.54%
$109.95
price down icon 0.07%
drug_manufacturers_general SNY
$54.46
price up icon 0.61%
Kapitalisierung:     |  Volumen (24h):